Single Enzyme Streamlines Production of All Four RNA Building Blocks

Why It Matters

By slashing the cost and complexity of NTP synthesis, the technology removes a major bottleneck for RNA‑based therapeutics and biotech, accelerating scale‑up and sustainability.

Key Takeaways

• MAN PPK2 converts all RNA nucleotides to NTPs.
• Uses cheap polyphosphate, lowering production costs.
• Enables one‑pot mRNA synthesis, simplifying workflows.
• Broad substrate specificity mirrors ancient enzymatic versatility.
• Potential to cut RNA vaccine manufacturing expenses.

Pulse Analysis

The production of nucleoside triphosphates (NTPs) has long been a cost‑driven obstacle for RNA‑centric technologies. Conventional pathways rely on a cascade of kinases, each requiring high‑energy donors such as ATP, which inflates both operational expense and waste. Moreover, the multi‑step nature of these processes complicates scale‑up, especially for large‑volume mRNA vaccine manufacturing where margins are razor‑thin. Industry players have therefore been hunting for a more streamlined, sustainable route to the essential building blocks of RNA.

Enter MAN PPK2, a polyphosphate kinase isolated from the marine bacterium *Mangrovibacterium marinum*. Unlike specialized kinases that act on a single substrate, MAN PPK2 exhibits broad specificity, efficiently phosphorylating nucleoside monophosphates and diphosphates of all four RNA bases in a single reaction. The enzyme draws its phosphate from polyphosphate (PolyP), an abundant, inexpensive polymer that sidesteps the need for costly ATP regeneration systems. Laboratory data published in *Nature Communications* demonstrate near‑quantitative yields of NTPs under mild conditions, and the same reaction mixture can be directly fed into T7 RNA polymerase for mRNA synthesis, collapsing what was once a multi‑day workflow into a one‑pot, hours‑long process.

The commercial ramifications are immediate. Lower NTP costs translate directly into cheaper mRNA vaccine batches, potentially reducing price barriers for emerging markets. Diagnostic firms can accelerate assay development by sourcing NTPs on‑demand rather than maintaining large inventories. In synthetic biology, the enzyme’s ancient‑style promiscuity offers a versatile tool for constructing minimalistic metabolic circuits. As the biotech sector pushes toward greener chemistry, the use of non‑toxic polyphosphate aligns with sustainability goals, positioning MAN PPK2 as a strategic asset for the next generation of RNA‑based products.